<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03744104</url>
  </required_header>
  <id_info>
    <org_study_id>JSVCT060</org_study_id>
    <nct_id>NCT03744104</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of A Quadrivalent Influenza Vaccine</brief_title>
  <official_title>Immunogenicity and Safety of a Quadrivalent Influenza Vaccine in Participants Aged Above 3 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Institute Of Biological Products</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Institute Of Biological Products</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the immunogenicity and safety of a quadrivalent influenza
      vaccine compared with a trivalent influenza vaccine in participants aged above 3 years.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants that presented seroconversion post injection</measure>
    <time_frame>30 days after inoculation</time_frame>
    <description>Seroconvertion is defined as: prevaccination Hemagglutination-inhibition test (HI) antibody titer ≤1:10 and postvaccination HI antibody titer ≥1:40, or prevaccination HI antibody titer ≥1:10 and a postvaccination increase by a factor of four or more.
Participants will be collected blood post first study injection, when blood samples will be taken for HI testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean of Hemagglutination-inhibition titre post first study injection</measure>
    <time_frame>30 days after inoculation</time_frame>
    <description>Geometric mean of Hemagglutination-inhibition test titre will be calculated for the different groups of participants post first study injection.
Participants will be collected blood post first study injection, when blood samples will be taken for HI testing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants that presented seroprotection post injection</measure>
    <time_frame>30 days after inoculation</time_frame>
    <description>Seroprotection is defined as postvaccination Hemagglutination-inhibition test (HI) antibody titer ≥ 1:40.
Participants will be collected blood post first study injection, when blood samples will be taken for HI testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited and Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Continuous observation for 30 days after two inoculations</time_frame>
    <description>For each group the incidence rate of subjects with solicited AE(s) with 95% confidence interval
For each group the incidence rate of subjects with unsolicited AE(s) with 95% confidence interval</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">2688</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Quadrivalent influenza vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quadrivalent influenza vaccine(containing 2 subtypes of B lineage)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trivalent influenza vaccine A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trivalent influenza vaccine (containing B/Victoria lineage)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trivalent influenza vaccine B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trivalent influenza vaccine (containing B/Yamagata lineage)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent influenza vaccine</intervention_name>
    <description>0.5 mL, intramuscular, one dose</description>
    <arm_group_label>Quadrivalent influenza vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent influenza vaccine A</intervention_name>
    <description>0.5 mL, intramuscular, one dose</description>
    <arm_group_label>Trivalent influenza vaccine A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent influenza vaccine B</intervention_name>
    <description>0.5 mL, intramuscular, one dose</description>
    <arm_group_label>Trivalent influenza vaccine B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over the age of three years,healthy population

          -  Subjects/ (and the guardian) informed consent, voluntarily participated and signed the
             informed consent form, with the ability to use thermometers, scales and to fill in
             diary cards as required

          -  To comply with the requirements of clinical trial program

          -  Temperature≤37.0℃ on day of enrollment

        Exclusion Criteria:

          -  A history of influenza virus infection or suspected infection Abnormal blood routine,
             blood biochemistry and urine routine examination indexes in last three months

          -  Any prior administration of influenza vaccine in last six months

          -  Allergy to any component in the vaccine, especially for egg allergy

          -  Allergy history of any previous vaccination or drug

          -  Acute episodes of chronic illness or acute illness on the day of vaccination

          -  Received a live vaccine within fourteen days prior to receiving the vaccine, or
             received a subunit or inactivated vaccine within seven days

          -  Congenital or acquired immune deficiencies, or treatment with immunosuppressive
             agents, such as long-term treatment with systemic corticosteroids

          -  Suffering from severe chronic diseases (such as Down's syndrome, diabetes, sicklemia
             or neurological disorders, Green's Barre syndrome)

          -  Asthma, required urgent treatment in last two years

          -  The blood products were received prior to the acceptance of the vaccine

          -  Known or suspected of respiratory disease, acute infection or chronic disease active
             period, HIV infection, cardiovascular disease, severe hypertension, malignant tumor
             during treatment, skin diseases

          -  History of epilepsy, convulsions, or a family history of psychosis

          -  Abnormal coagulation function (such as coagulation factor deficiency, coagulation
             disorders, platelet abnormalities), or obvious bruising or coagulopathy

          -  Plan to move or leave the area for an extended period of time before the end of the
             study

          -  Under anti-tb treatment

          -  Any prior administration of other research medicine/vaccine in last one month

          -  Women are pregnant or in the near future planned pregnancy or pregnancy test positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hu Yuemei, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Province Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chen Dandan, MS</last_name>
    <phone>86-021-62750096-4210</phone>
    <email>ddchen.sh@sinopharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Suining County Center for Disease Control and Prevention</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhou fang, BS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinyi County Center for Disease Control and Prevention</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Sun Weiguang, BS</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2018</study_first_posted>
  <last_update_submitted>November 16, 2018</last_update_submitted>
  <last_update_submitted_qc>November 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT03744104/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

